Publications by authors named "H Itonaga"
Background Aims: Allogeneic hematopoietic stem cell transplantation (HSCT) improves outcomes for myelodysplastic syndrome (MDS) patients, but relapse rates remain high, and postrelapse treatment options are limited. Therefore, this study aimed to identify the factors contributing to the response to donor lymphocyte infusion (DLI) in relapsed MDS patients post-HSCT.
Methods: This study included 107 patients with relapsed and DLI-treated MDS who underwent their first HSCT between 2002 and 2022 and were registered in the Transplant Registry Unified Program.
This study retrospectively compared outcomes of various allogeneic haematopoietic cell transplantation (allo-HCT) platforms in patients with adult T-cell leukaemia/lymphoma. Platforms included human leukocyte antigen (HLA)-haploidentical-related donors using post-transplant cyclophosphamide (PTCY), HLA-matched related donors (MRD), HLA-matched unrelated donors (MUD) and cord blood transplantation (CBT). Patients who underwent their first allo-HCT between 2016 and 2021 were included.
View Article and Find Full Text PDFArticle Synopsis
- A 63-year-old man with relapsed acute myeloid leukemia underwent a third stem cell transplant and was given voriconazole to prevent fungal infections.
- On day 42 post-transplant, he developed septic arthritis without the typical skin signs associated with fungal infections.
- Despite surgery and treatment with liposomal amphotericin B, he died due to a resistant fungal infection, highlighting the need to consider azole-resistant infections as potential causes of septic arthritis in similar patients.
Article Synopsis
- * A retrospective analysis of 32 patients aged 70 and older showed that those treated with MOG-containing chemotherapy had a median survival time of 18.1 months and a 2-year overall survival rate of 45%, indicating improved outcomes compared to previous treatments.
- * Adverse events from MOG treatment were similar to those seen in past studies, and while comorbidity impacted survival, the intensity of MOG treatment did not, suggesting a different action mechanism compared to
Article Synopsis
- The study investigates the effectiveness of the fludarabine/intravenous busulfan (FB4) regimen in patients with myelodysplastic syndrome (MDS) undergoing stem cell transplantation from unrelated donors, comparing FB4 alone, FB4 with anti-thymoglobulin (ATG), and FB4 with low-dose total body irradiation (TBI).
- Results show that the combination of FB4 with low-dose ATG significantly improved overall survival (OS) and reduced nonrelapse mortality (NRM) compared to FB4 alone, whereas the FB4 with TBI did not demonstrate notable advantages over the FB4 regimen.
- The study highlights that using FB4 plus low-dose ATG is associated with better outcomes